KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Rigel Pharmaceuticals (RIGL) EBT (2016 - 2025)

Historic EBT for Rigel Pharmaceuticals (RIGL) over the last 16 years, with Q3 2025 value amounting to $27.6 million.

  • Rigel Pharmaceuticals' EBT rose 12236.53% to $27.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $114.3 million, marking a year-over-year increase of 284601.91%. This contributed to the annual value of $18.4 million for FY2024, which is 17319.76% up from last year.
  • Latest data reveals that Rigel Pharmaceuticals reported EBT of $27.6 million as of Q3 2025, which was up 12236.53% from $60.0 million recorded in Q2 2025.
  • In the past 5 years, Rigel Pharmaceuticals' EBT ranged from a high of $60.0 million in Q2 2025 and a low of -$27.4 million during Q1 2022
  • Over the past 5 years, Rigel Pharmaceuticals' median EBT value was -$5.7 million (recorded in 2023), while the average stood at $868736.8.
  • In the last 5 years, Rigel Pharmaceuticals' EBT tumbled by 16649.95% in 2022 and then surged by 592349.51% in 2025.
  • Over the past 5 years, Rigel Pharmaceuticals' EBT (Quarter) stood at -$22.7 million in 2021, then soared by 106.17% to $1.4 million in 2022, then plummeted by 47.39% to $737000.0 in 2023, then surged by 1965.4% to $15.2 million in 2024, then surged by 81.45% to $27.6 million in 2025.
  • Its EBT was $27.6 million in Q3 2025, compared to $60.0 million in Q2 2025 and $11.5 million in Q1 2025.